Zhejiang Shengda Bio-Pharm Co., Ltd. Stock price

Equities

603079

CNE100002W43

Food Processing

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
13.96 CNY -9.99% Intraday chart for Zhejiang Shengda Bio-Pharm Co., Ltd. +31.82% -4.19%
Sales 2021 790M 109M Sales 2022 738M 102M Capitalization 2.15B 298M
Net income 2021 75M 10.39M Net income 2022 31M 4.29M EV / Sales 2021 3.27 x
Net cash position 2021 378M 52.3M Net cash position 2022 288M 39.89M EV / Sales 2022 2.52 x
P/E ratio 2021
39.3 x
P/E ratio 2022
69.7 x
Employees 1,152
Yield 2021
0.81%
Yield 2022
0.48%
Free-Float 42.01%
More Fundamentals * Assessed data
Dynamic Chart
China stocks rise as strength in banks offsets developers' falls RE
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. announces an Equity Buyback for CNY 34 million worth of its shares. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. authorizes a Buyback Plan. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. announced that it expects to receive CNY 500 million in funding CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day-9.99%
1 week+31.82%
Current month+45.42%
1 month+46.64%
3 months-3.66%
6 months+4.57%
Current year-4.19%
More quotes
1 week
12.00
Extreme 12
15.51
1 month
9.05
Extreme 9.05
15.51
Current year
7.01
Extreme 7.01
15.51
1 year
7.01
Extreme 7.01
16.24
3 years
7.01
Extreme 7.01
22.00
5 years
7.01
Extreme 7.01
43.91
10 years
7.01
Extreme 7.01
43.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 13-12-12
Director of Finance/CFO 44 22-04-26
Director/Board Member 38 11-12-31
Members of the board TitleAgeSince
Director/Board Member 64 13-09-23
Director/Board Member 59 19-12-17
Director/Board Member 62 21-09-16
More insiders
Date Price Change Volume
24-03-28 13.96 -9.99% 26,258,370
24-03-27 15.51 +10.00% 1,091,726
24-03-26 14.1 +9.98% 5,163,849
24-03-25 12.82 +10.04% 8,265,658
24-03-22 11.65 +10.01% 5,204,415

End-of-day quote Shanghai S.E., March 27, 2024

More quotes
ZHEJIANG SHENGDA BIO-PHARM CO., LTD. is a China-based company principally engaged in the research, development, production and sales of vitamins and biological preservatives. Its vitamin products mainly include biotin and folic acid. Its biological preservative products mainly include natamycin and nisin. The Company distributes its products in domestic market and to overseas markets.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Zhejiang Shengda Bio-Pharm Co., Ltd. - Shanghai S.E.